ANNX Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Annexon, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.14 |
| 52 Week High | US$8.40 |
| 52 Week Low | US$2.27 |
| Beta | 1.23 |
| 11 Month Change | -30.54% |
| 3 Month Change | -15.88% |
| 1 Year Change | 88.97% |
| 33 Year Change | -62.48% |
| 5 Year Change | n/a |
| Change since IPO | -71.06% |
Recent News & Updates
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely
Sep 27
Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS
Aug 17Recent updates
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely
Sep 27Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS
Aug 17Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place
Jun 04Annexon: Unforced Error Sullies Prospects
Apr 03Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation
Nov 10Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
Jul 25Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
Apr 11Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?
Feb 14We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully
Dec 28Annexon started as a buy at Jefferies on market potential of candidates, data catalysts
Sep 16Annexon: A First Take
Aug 21Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02
Aug 08Annexon to raise $130M in stock and warrant offering
Jul 08We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate
Apr 16Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth
Jan 01Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth
Sep 08We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth
May 22We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth
Feb 06
Dosing underway in Annexon's Phase 2/3 study of monoclonal antibody in Guillain-Barré Syndrome
Dec 21Annexon Biosciences EPS misses by $0.43
Nov 16Shareholder Returns
| ANNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -16.0% | 2.5% | 2.2% |
| 1Y | 89.0% | 16.1% | 31.6% |
Return vs Industry: ANNX exceeded the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: ANNX exceeded the US Market which returned 31.7% over the past year.
Price Volatility
| ANNX volatility | |
|---|---|
| ANNX Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ANNX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ANNX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 84 | Doug Love | www.annexonbio.com |
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications.
Annexon, Inc. Fundamentals Summary
| ANNX fundamental statistics | |
|---|---|
| Market cap | US$547.89m |
| Earnings (TTM) | -US$117.50m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.7x
P/E RatioIs ANNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANNX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$117.50m |
| Earnings | -US$117.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.10 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ANNX perform over the long term?
See historical performance and comparison